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development (Gollenberg et al., 2010). However, among girls with
higher concentrations of urinary Cd, blood lead levels were
inversely related to inhibin b levels.
The aims of this analysis were to: 1) determinewhether urinary
cadmium concentration differed by age and race/ethnicity in a
cohort of girls and 2) evaluate whether cadmium was associated
with the attainment of menarche and breast and pubic hair
development.
Methods: The GRowth and LifeStyle (GRLS) study is a cohort of 230
girls, ages 10 to 13 years at baseline, residing in the San Francisco
Bay Area. A total of 211 girls provided overnight urine specimens
and completed a baseline interview and self-assessment of breast
and public hair development andwere followed for up to two years
for the attainment of menarche. Cadmium and creatinine con-
centrations were measured using inductively-coupled plasma
mass spectrometry (ICP/MS). We used Cox regression to evaluate
whether cadmium was associated with age at menarche and cu-
mulative logit regression to evaluate whether cadmium was
associated with breast and pubic hair development.
Results: The baseline mean creatinine-adjusted cadmium concen-
tration was 0.24 mg/g creatinine (SD ¼ 0.11 mg/g) and was highest
among 10-year olds (0.29 mg/g creatinine) and decreased with
increasing age (mean among 13-year olds ¼ 0.23 mg/g; p-trend ¼
0.05). Chinese girls had higher cadmium levels than non-Hispanic
Whites (0.30 vs. 0.23 mg/g creatinine; p ¼ 0.006).
Girls with the highest unadjusted cadmium levels (¼ 0.4 vs.
<0.2 mg/L) were less likely to have attained menarche (hazard ratio
¼ 0.42; 95% conﬁdence interval ¼ 0.23-0.78) and have a high
Tanner stage of pubic hair development (odds ratio ¼ 0.24; 95%
conﬁdence interval ¼ 0.07-0.81). Breast development stage was
not associated with cadmium concentration.
Conclusions: These ﬁndings suggest that a higher Cd body burden
may delay androgenic development (the ﬁrst stage of puberty) and
menarche. This is consistent with evidence from animal studies
suggesting that Cd exposure may delay the onset of estrus.
Whether this is due to ovotoxicity, as proposed for animals, is
unknown at this time.
Sources of Support: This research was supported by the California
Breast Cancer Research Program (award no. 17IB-0016) and the
National Institutes of Health (award no. U54CA100949).21.
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Purpose: Many adolescents with high-risk sexual behaviors only
receive health care episodically in the emergency department (ED).
ED visits offer an opportunity to deliver brief interventions to
improve health, but no proven ED-based brief intervention to
reduce sexual risk behaviors exists. The study objectives were to 1)
assess feasibility of a novel intervention using National Research
Council criteria (effectiveness, efﬁciency, and satisfaction), and 2)
examine impact on attitudes and behaviors.Methods: In this cross-sectional pilot study, sexuallyactive patients
aged 14-19 years presenting to a Midwestern ED were recruited to
receive an intervention to reduce sexual risk behaviors. The inter-
vention, based on motivational interviewing (MI), included agenda
setting, exploration of behaviors, decisional balance exercise,
tailored feedback, and referral to the hospital-afﬁliated Adolescent
Clinic. Individually-tailored sessions offered provision of condoms,
prescriptions for emergency contraception, and/or testing for
sexually transmitted infections (STI). Participants completed a
survey and intervention at baseline, an immediate post-interven-
tion survey at Time 1, and a three-month phone follow-up survey at
Time 2. Surveys assessed sexual behaviors, attitudes and self-efﬁ-
cacy regarding condoms and birth control. Additional questions
included: demographics (baseline), satisfaction, and ﬁdelity mea-
sures (Time 1). Feasibility criteria were: 1) Subject rated interven-
tionist ﬁdelity toMI principles (Likert scale 1¼ stronglyagree to 4¼
strongly disagree), 2) Session duration (minutes), and 3) Subject
satisfaction (Likert scale 1 ¼ not at all to 5 ¼ very).
Results: Sixty-six subjects (96% of approached) completed the
screening with 24 (37%) qualifying for enrollment by reporting
previous sexual activity. Of those, 20 (83%) participated (mean age
16.2 years; 60% female). Subjects somewhat or strongly agreed that
the interventionist: 1) “was easy to talk to” (90%), 2) “was con-
cerned about me” (78%), 3) “understood me” (89%), 4) “treated me
like an equal” (89%), and 5) “did not push me into something I
wasn’t ready for” (80%). The mean duration was 15.7 minutes. All
subjects were fairly (20%) or very (80%) satisﬁed. One subject
tested positive for Chlamydia trachomatis and received treatment
at Adolescent Clinic. When offered, most (59%) accepted condoms
and 71% accepted a prescription for emergency contraception. Five
subjects kept appointments at Adolescent Clinic where additional
services were provided: STI testing (n ¼ 2), birth control pre-
scribed/administered (n ¼ 2), provision of condoms (n¼1), and
inﬂuenza vaccination (n ¼ 1). Fifteen subjects (75%) were reached
for 3-month follow-up. Among those reporting sex since enroll-
ment (n ¼ 6), 67% reported continued condom use at most recent
sex. There were positive trends in attitudes towards condoms and
birth control self-efﬁcacy.
Conclusions: This ED-based intervention was delivered with high
ﬁdelity and relative rapidity, and resulted in high satisfaction
among these sexually active adolescents. A considerable propor-
tion received health services essential for optimal sexual health.
Studies to assess efﬁcacy appear warranted.
Sources of Support: This work was supported in part by Frontiers:
The Heartland Institute for Clinical and Translational Research
(University of Kansas Medical Center’s CTSA; KL2TR000119-02).
The contents are solely the responsibility of the authors and do not
necessarily represent the ofﬁcial views of the NIH, NCRR, or NCATS.
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VARIATIONS IN PROVIDER RESPONSES TO AUTOMATED
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Johns Hopkins University.
Purpose: Vaccine coverage rates are far lower for adolescents than
they are for younger children. Providers are more likely to deliver
recommended vaccines to adolescents at standard preventive
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focused visits. An automated clinical decision support tool pro-
vides actionable and up-to-date information at the point of care to
reduce missed opportunities for vaccination of adolescents
regardless of when they engage in care. The purpose of this study is
to determine the degree to which vaccine delivery following a
vaccine computerized clinical decision support system (CCDSS)
varied by patient characteristics (age, gender, and number of vac-
cines due) and visit characteristics (preventive vs. problem
focused).
Methods: We implemented a CCDSS in a single urban teaching
clinic where residents, adolescent medicine fellows, and nurse
practitioners provide pediatric primary care, adolescent medi-
cine and HIV specialty care. This tool provided an alert to
providers, using the clinic’s electronic medical platform, when
adolescents ages 11-21 were due for any recommended vaccine,
based on standard Center for Disease Control & Prevention
schedules. These alerts were triggered for all types of visits,
including acute visits. We examined factors associated with
vaccination including age (using following age categories: 11-12,
13-17, and ¼18); gender; type and number of vaccines due; and
visit type using chi-squared and multiple logistic regression
analyses.
Results: In a 15-month period, 5943 alerts for vaccines due were
sent during 3,672 visits among 1,936 unique patients. The number
of alerts per visit ranged from 1-5 vaccines (Mean 1.6, SD 0.89).
Alerts were most common for HPV (47.7%) and MCV (27.2%).
Hepatitis B (2.2%), IPV (2.0%) and MMR (1.7%) were less common.
Overall, 45.8% of reminders resulted in vaccine administration at
that visit. Response rates were highest for younger adolescents
(55.3% for ages 11-12, compared to 47.1% for ages 13-17 and 34.1%
for those ¼18, p¼<0.001), and higher for males than females
(51.4% vs. 40.5%, p¼<0.001). Response rates were highest when
patients were due for 3 vaccines (57.6%) and lowest when patients
were due for only 1 vaccine (42.5%) (p < 0.001). In the ﬁnal
adjusted model, males had a 46% greater odds to receive vaccines
in response to alerts than females (OR 1.46, 95% CI 1.28-1.67), while
older adolescents were less likely to receive vaccinations as
compared to 11-12 year olds (13-17yo: OR 0.79 (95% CI 0.67-0.94) &
¼18yo: OR 0.46 (95% CI 0.37-0.55). Patients requiring 2 or 3 vac-
cinations were more likely to receive them than those requiring
only 1 (OR 1.40, (95% CI 1.17-1.67) and OR 1.58 (95% CI 1.29-1.92)
respectively). Provider response to CCDSS did not differ by visit
type in ﬁnal model.
Conclusions: The use of an electronic alert system for adolescents
has potential for improving vaccine administration by promoting
vaccination during early adolescence and targeting certain groups
that would otherwise be missed by vaccines targeting only fe-
males. Additional efforts may need to be used to promote vacci-
nation in older adolescents.
Sources of Support: SAHM Improving Understanding of Adoles-
cent Vaccination through Innovative Local Public Health Demon-
stration Grant.
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Purpose: To assess the impact of gender-speciﬁc human papillo-
mavirus (HPV) vaccination recommendations and demographic
characteristics on: (1) early uptake, (2) coverage, and (3) series
completion for males and females.
Methods: We analyzed HPV vaccination for 11-18 year-olds using
the Citywide Immunization Registry (CIR), a database containing
vaccinations administered in New York City. Initiation was deﬁned
as receipt of>¼1 dose, and timely completion as>¼3 doses within
12-months of initiation. Patient-speciﬁc variables included age,
gender, and insurance status. Practice-speciﬁc variables included
practice-type, number of Tdap vaccines reported (proxy for prac-
tice size), and percent poverty in practice location. We evaluated
factors associated with early initiation (within 1 year of routine
gender-speciﬁc recommendations [females: 3/23/07, males: 12/23/
11]), and timely completion.
Results: Of the 1,494,767 11-18 year-olds in the CIR from 2005-
2012, 50.2% were male, 56.7% received their vaccines in private
practices, 57.9% in practices in the highest tertile of adolescent
patient population size, and 46.9% in practices in the highest
poverty tertile areas. Of all 13-18 year-olds as of July 2013, 47.2%
received >¼1 dose, with 44.3% initiating at <¼12 years, 41.6% at
13-15 years, and 14.1% at 16-18 years. Within one year of routine
recommendations for their gender, 28.8% of 13-18 year-old fe-
males vs. 29.3% of males had initiated vaccination. Both males
and females had signiﬁcantly greater odds of early uptake if they
were publicly insured, seen at a practice with moderate-to-large
number of adolescents, and/or at a public hospital/community
health clinic (PH/CHC) or private hospital (adjusted odds ratios
(AORs) range 1.29-2.22; 95% CI range for all AORs 1.26, 2.29).
Being seen at a practice in a high vs. low poverty area was
associated with early uptake for males (AOR 1.61; 95% CI 1.57,
1.66) but lower uptake for females (AOR 0.96; 95% CI 0.93, 0.99).
Half of those who initiated HPV vaccination in 2011 were male;
of those who initiated, females were more likely to complete
within 12 months (females 38.4% vs. males 35.7%; p < 0.0001).
For both genders, those seen at low or mid-level poverty area
practices or practices with more adolescents had greater odds of
completion (AORs range 1.09-1.29; 95% CI range 1.02,1.41); those
seen at a private hospital vs. private practice and those unin-
sured had lower odds of completion (AORs range 0.75-0.88; 95%
CI range 0.71, 0.93). However, males seen at PH/CHC were more
likely than those seen at private practice to complete (AOR 1.10;
95% CI 1.05, 1.16).
Conclusions: Despite the pre-existence of permissive recom-
mendations for males, male uptake in the ﬁrst year after routine
recommendation was similar to that of females in their ﬁrst year
post-routine recommendations. While males seen in higher
poverty areas were more likely to initiate, both males and fe-
males from those areas were less likely to complete the HPV
vaccine series. Similarly, although both genders seen in private
practices were less likely to initiate, females seen at those
practices were more likely to complete, while males were less
likely. In 2011, half of those initiating HPV vaccination were male.
Completion rates for both genders remained below Healthy
People 2020 targets.
Sources of Support: CUMC Adolescent Medicine Fellowship.
